Revenue Recognition (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended	41 Months Ended	51 Months Ended
	Feb. 28, 2019	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Dec. 31, 2021	Sep. 30, 2019	Aug. 31, 2019
Deferred revenue, Long-term		$ 21,511		$ 20,001	$ 20,001	$ 21,511
Increased (decreased) revenues		(9,200)	$ 6,400
(Increased) decreased net loss		$ (9,200)	$ 6,400
(Increased) decreased net loss per share		$ (0.08)	$ 0.06
Other assets		$ 19,288		18,330	18,330	19,288
Deferred revenue		38,090	$ 34,457	30,778	30,778	38,090	$ 28,722
Deferred revenue, current portion		16,579		10,777	10,777	16,579
Total revenues		241,756	194,133
Deferred revenue, long-term portion		21,511		20,001	20,001	21,511
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		3,988	3,889
Product
Revenue recognized		5,700	1,400
Cost of revenues		$ 147,754	$ 102,670
Billing collection period (in months)		18 months
(Increased) decreased net loss per share		$ 0.05	$ 0.01
Total revenues		$ 237,797	$ 190,002
Licensing and other
Cost of revenues		370	545
Total revenues		3,959	$ 4,131
Genetic testing services
Deferred revenue, current portion		14,200				14,200
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		$ 3,700
Laboratory distribution partners | Product | Minimum
Billing collection period (in months)		2 months
Laboratory distribution partners | Product | Maximum
Billing collection period (in months)		3 months
BGI Genomics
Revenue recognized		$ 100		8,500		44,000
Proceeds from license agreement	$ 50,000
Agreement term	10 years
Deferred revenue, Long-term		19,800				19,800
Other assets		8,400				8,400
Prepaid expenses and other current assets		2,400		$ 4,000	4,000	2,400
Deferred revenue, long-term portion		19,800				19,800
BGI Genomics | Sequencing services
Other assets		6,000				6,000		$ 6,000
BGI Genomics | Sequencing products
Other assets								4,000
BGI Genomics | Sequencing products and services
Other assets		1,600				1,600		$ 10,000
BGI Genomics | Royalty
Revenue recognized		600
Foundation Medicine ("FMI")
Revenue recognized		200
Proceeds from license agreement		$ 19,300			$ 16,800
Agreement term		5 years
Deferred revenue, Long-term		$ 1,700				1,700
Deferred revenue, current portion		2,400				2,400
Deferred revenue, long-term portion		$ 1,700				$ 1,700
Foundation Medicine ("FMI") | Upfront licensing fees and prepaid revenues
Initial transaction price									$ 13,300
Foundation Medicine ("FMI") | Developmental, regulatory, and commercial milestones
Initial transaction price									$ 32,000